| fluvestrant 250mg versus exemestane | |||
| 9238UK/0005 (fluvestrant alone), 0 NCT00944918 | fulvestrant Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression
versus exemestane oral, once daily until disease progression. | postmenopausal locally advanced / metastatic breast cancer patients who have progressed on NSAIs | double-blind Korea |
| SoFEa (Johnston) fluvestrant alone, 2012 NCT00253422 | fulvestrant intramuscularly (IM) on days 1, 15, and 29 and then once monthly versus exemestane once daily | Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors | UK |
| fulvestrant + anastrozole versus exemestane | |||
| 9238UK/0005 (combination), 0 NCT00944918 | versus | postmenopausal locally advanced / metastatic breast cancer patients who have progressed on NSAIs | double-blind Korea |
| SoFEa (Johnston) combination, 2012 NCT00253422 | Fulvestrant With Concomitant Anastrozole versus Exemestane | Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors | |
| fulvestrant 500mg versus fulvestrant 250mg | |||
| D6997L00021, 3000 NCT01300351 | Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only versus Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only | Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment | double-blind China |
| CONFIRM (Di Leo), 2010 NCT00099437 | fulvestrant 500 mg
(500 mg intramuscularly [IM] on day 0, then 500 mg IM on days 14 and 28 and every 28 days
thereafter) versus fulvestrant 250 mg every 28 days | women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment | double-blind US |
| FINDER 2, 2010 NCT00313170 | 500 mg (high dose [HD]; 500 mg/month plus 500 mg on day 14 of Month 1). versus fulvestrant: 250 mg/month (approved dose [AD]); | Western postmenopausal women recurring or progressing after prior endocrine therapy | |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
